Galectin Therapeutics Announces Completion of Patient

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Galectin Therapeutics Announces Completion of Patient Recruitment in its Phase 2 Trial with GR-MD-02 in NASH Patients with Cirrhosis

NORCROSS, Ga., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT ), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces the completion of patient recruitment in its Phase 2 clinical trial with GR-MD-02 in patients with non-alcoholic steatohepatitis (NASH) with cirrhosis (the NASH-CX trial).  The Company expects to report the topline results of this trial in December 2017, as previously planned.

“We are pleased that patient recruitment in our NASH-CX trial was completed ahead of our original expectations,” said Peter G. Traber, M.D., Galectin’s president, chief executive officer and chief medical officer.  “This is one of two Phase 2 trials we are conducting in subjects with NASH, and it is designed to assess the efficacy of our lead compound GR-MD-02 in patients with NASH cirrhosis.  This trial was designed and is being conducted with a primary endpoint that the U.S. Food and Drug Administration views may be a surrogate for outcomes for registration trials in this patient population.”

The NASH-CX trial has recruited and consented 290 patients, with the goal to enter 156 liver biopsy-confirmed NASH cirrhosis patients into the treatment phase. Patients are required to meet major screening criteria before starting the treatment phase of the trial including a hepatic venous pressure gradient (HVPG) > = 6 mm Hg, confirmation of NASH fibrosis stage by biopsy (Brunt fibrosis stage 4, modified Ishak fibrosis stage 5 or 6), amongst other criteria. The screening period from recruitment to initiating treatment is approximately 8 weeks and the screen fail rate is approximately 40 percent of patients recruited, as per the original study plan. Therefore, the study should meet its full complement of treated patients to meet the previously stated goal of topline data readout in December 2017.

Enrolled patients are receiving either 8 mg/kg or 2 mg/kg of GR-MD-02 or placebo every other week for 52 weeks, for a total of 26 doses. The primary study endpoint is a reduction in HVPG. Patients treated with GR-MD-02 will be evaluated to determine the change in HVPG as compared to patients treated with placebo. HVPG will be correlated with secondary endpoints of liver biopsy fibrosis staging, measurement of liver stiffness (FibroScan (R) ), and assessment of liver metabolism ( 13 C-methacetin breath test, Exalenz), which are non-invasive measures of the liver that may be used in future studies. More information on the NASH-CX trial may be found in a post on Dr. Traber’s blog, CEO Perspectives and at www.clinicaltrials.gov .

“NASH cirrhosis, and indeed all etiologies of cirrhosis, represent a large unmet medical need with no currently approved medical therapies,” said Dr. Traber. “A drug that can halt progression of, or reverse existing fibrosis, in NASH cirrhosis patients would be a welcome therapeutic intervention that may prevent complications, alleviate the need for liver transplant, and prevent death. While progression to cirrhosis in NASH is not common, the enormous number of people with fatty liver disease globally suggests that nearly 20 million people currently with fatty liver disease across the world may die of their disease. Read more about the global scope of this problem in my recent CEO Perspective .”

About GR-MD-02 GR-MD-02 is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of fatty liver disease and fibrosis. Galectin-3 plays a major role in diseases that involve scarring of organs including fibrotic disorders of the liver, lung, kidney, heart and vascular system. The drug binds to galectin proteins and disrupts their function. Preclinical data in animals have shown that GR-MD-02 has robust treatment effects in reversing liver fibrosis and cirrhosis.

About Fatty Liver Disease with Advanced Fibrosis and Cirrhosis Non-alcoholic fatty liver disease (NAFLD) has become the most common disease of the liver, generally associated with the rise in obesity rates.  NAFLD is characterized by the presence of fat in the liver in people who consume little or no alcohol, and when associated with inflammation and cell damage is called non-alcoholic steatohepatitis (NASH). Over time, patients with NASH can develop fibrosis, or scarring of the liver, which may progress to severe fibrosis, called cirrhosis. Approximately one in four people in the world have NAFLD, with 5% of those developing cirrhosis, and 2% eventually dying of the disease. These data translate into ~20,000,000 liver-related deaths among patients currently alive with NAFLD. There are no drug therapies approved for the treatment of NASH, liver fibrosis, or cirrhosis, for which liver transplant is the only treatment available. A recent analyst estimate indicated that by 2025 the worldwide market for NASH treatments could approach $35 billion.

About Galectin Therapeutics Galectin Therapeutics is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, which are key mediators of biologic function. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. The Company is pursuing a development pathway to clinical enhancement and commercialization for its lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com .

Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as “may,” “estimate,” “could,” “expect” and others. They are based on management’s current expectations and are subject to factors and uncertainties that could cause actual results to differ materially from those described in the statements. These statements include those regarding the hope that Galectin’s development program for GR-MD-02 will lead to the first therapy for the treatment of fatty liver disease with advanced fibrosis and/or cirrhosis . Factors that could cause actual performance to differ materially from those discussed in the forward-looking statements include, among others, that Galectin may not be successful in developing effective treatments and/or obtaining the requisite approvals for the use of GR-MD-02 or any of its other drugs in development. The Company’s current clinical trial and any future clinical studies may not produce positive results in a timely fashion, if at all, and could prove time consuming and costly. Plans regarding development, approval and marketing of any of Galectin’s drugs are subject to change at any time based on the changing needs of the Company as determined by management and regulatory agencies. Regardless of the results of any of its development programs, Galectin may be unsuccessful in developing partnerships with other companies or raising additional capital that would allow it to complete its ongoing or subsequent trials.  Galectin has incurred operating losses since inception, and its ability to successfully develop and market drugs may be impacted by its ability to manage costs and finance continuing operations. For a discussion of additional factors impacting Galectin’s business, see the Company’s Annual Report on Form 10-K for the year ended December 31, 2015, and subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause its views to change, management disclaims any obligation to update forward-looking statements.

Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc.

Contacts: Jack Callicutt, Chief Financial Officer (678) 620-3186 ir@galectintherapeutics.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Radnostix Sees Mixed Results, Plans Strategic Shift

Updated Category News Views 44

Radnostix: A Rocky Third Quarter with Glimmers of Hope Alright, sit back and digest this: Radnostix, the company once known as International Isotopes Inc., is currently in the midst of a renovation of sorts. They just reported their financial results for the third quarter of 2026, and honestly, they're a mixed bag. Revenue Falls but Theranostics Shines Quarterly revenue...

Continue Reading
TCL Unveils Black Friday Steals on Smart Devices

Updated Category News Views 148

TCL's Big Move This Holiday Season When was the last time you saw a deal that actually made you stop and check your wallet? Well, TCL is giving you a reason to dig deep this Black Friday and Cyber Monday. They're slashing prices across smartphones and tablets, trying to elbow their way into your shopping cart with discounts up to $150. Now that's the kind of aggressive...

Continue Reading
Charlotte's Top-Tier Home Sales Surge: A $15M Milestone

Updated Category News Views 134

Charlotte's Luxury Market: A Rapid Ascent Folks, buckle up, because the luxury home market in Charlotte isn't just on the rise—it's practically sky-high. Back in 2016, the idea of splashing out over $5 million on a house was almost unheard of in this neck of the woods. Only one brave soul did it at the time. Fast forward to this past year, and things are looking starkly...

Continue Reading
Painter's Accessory Aims to Revolutionize Convenience

Updated Category News Views 64

Crafty New Invention Targets Painters' Ease Ever find yourself tangled in paintbrushes and rollers while trying to get that perfect coat on the wall? Well, a painter from Bracebridge, Ontario, has had it with the struggle and is looking to stir the pot with their latest invention, the NU LIFE LINER. It's sleek, it's practical, and it's aimed at flipping the painting game...

Continue Reading
DarioHealth's New Research Tackles Healthcare Cost Estimation

Updated Category News Views 124

Unpacking Dario's Bold Surgical Strike at ISPOR Europe Alright, folks, DarioHealth is shaking up the stage with their new methodology that could very well carve a new path in how we size up digital healthcare savings. Presented at ISPOR Europe 2026, Dario's tactic bypasses the sluggish wait on medical claims data, instead offering an evidence-driven peek at potential...

Continue Reading
LA Hospitals Shine in Pulmonary Excellence Nationwide

Updated Category News Views 120

Los Angeles Community Hospitals' Recent Recognition You ever stroll into a hospital and wonder if you’re really getting the best care? Well, the folks over at Los Angeles Community Hospitals, covering LA, Norwalk, and Bellflower, just got a big nod from Healthgrades—yeah, the site everyone's checking to find decent healthcare options. They’ve landed among the top...

Continue Reading
Loyalty Programs Cut $1500 Annually for Consumers

Updated Category News Views 122

Loyalty Programs: An Essential Tool for Households In a world where every dollar counts, retail loyalty programs have become more than just a marketing strategy—they're lifelines for American households scraping through each month. According to fresh research by the Retail Industry Leaders Association (RILA) and conducted by market research leader Circana, these...

Continue Reading
AvidXchange Acquisition Faces Fairness Investigation

Updated Category News Views 100

Unpacking the AvidXchange Turmoil Staring at the ticker tape feels like watching a drama unfold, and today it's all about AvidXchange Holdings, Inc. (NASDAQ: AVDX). Levi & Korsinsky, LLP has launched an investigation into the fairness of its acquisition, and let me tell you, when the suits start poking around, it means someone smells a rat. The deal in question? A buyout...

Continue Reading
VIO Med Spa’s Black Friday Event: Aesthetic Savings

Updated Category News Views 270

Kicking Off the Holiday Season with a Glow Just when you think the holiday hustle can't get busier, VIO Med Spa is opening the gates of rejuvenation just in time to add yourself to that epic list. Starting November 16, VIO launches its Black Friday extravaganza—a deal-laden kick-off that means smooth skin and sharper looks are up for grabs. Member Benefits and Public...

Continue Reading
NVIDIA Faces Turbulent Storm with CEO Resignation

Updated Category News Views 102

Huang's Unexpected Exit and NVIDIA's Rocky Road Well, talk about drama in Silicon Valley. When executives start stumbling, it's not just some PR nightmare—it's a full-on crisis. NVIDIA's co-founder and CEO Jensen Huang is calling it quits, and not on some smooth, idyllic note. No, this is the kind of exit that investors dread. You’ve got affairs, security concerns,...

Continue Reading

Top 5 Most Recently Viewed Articles

Starbucks Earnings Anticipation: Growth and Challenges Ahead

Updated Category News Views 152

Starbucks Earnings Preview Starbucks (NASDAQ: SBUX) is set to announce its quarterly earnings shortly. Investors are keenly awaiting the report, reflecting hopes for positive outcomes and growth perspectives. The anticipation surrounding this announcement includes significant insights that could shape investor sentiment. Expected Earnings Report Analysts have projected...

Continue Reading
Understanding the Current Options Trends of T-Mobile US

Updated Category News Views 192

Insights into T-Mobile US Options Activity Recently, T-Mobile US has witnessed a stark shift in options trading, driven by significant market movements. A detailed examination of the options history for T-Mobile US (NASDAQ: TMUS) has unveiled a string of unusual trades that indicate a complex trading atmosphere. Delving deeper, our analysis shows that about 41% of traders...

Continue Reading
Arteris, Inc. Boosts Team with New Inducement Stock Awards

Updated Category News Views 282

Arteris, Inc. Announces Substantial Inducement Stock Grants Arteris, Inc. (Nasdaq: AIP), a prominent provider of system IP for accelerating semiconductor innovation, recently revealed an exciting development regarding its workforce expansion. The company has made the decision to grant a total of 109,000 restricted stock units (RSUs) to four newly hired employees as part...

Continue Reading
Enhanced Drill Insights from Freeman Gold's Latest Project

Updated Category News Views 217

Freeman Gold Unveils Significant Drill Results Freeman Gold Corp. (TSXV: FMAN, OTCQB: FMANF) has recently shared exciting outcomes from its expanded drilling initiative, which aims to enhance the Lemhi Gold Project. The results of the three drill holes from the southern segment of their 2025 drilling program indicate potential for substantial gold deposits, further...

Continue Reading
Exploring the Growth of the Paper and Paperboard Market

Updated Category News Views 146

Forecasting the Future of Paper and Paperboard Packaging The global paper and paperboard container and packaging market is on track to experience remarkable growth, with estimated revenues soaring by USD 59.15 billion during the forecast period. The projected CAGR for this timeframe stands at 4.39%, fueled by a surge in the demand for specialized containers and innovative...

Continue Reading